Local drugmakers in Nigeria kick against new government policies

7 July 2015

The Pharmaceutical Manufacturers Association of Nigeria (PMGMAN) has raised concerns over the New Drug Distribution Guideline, NDDG, and Common External Tariff (CET), saying that they are threats to the survival of the local pharmaceutical industry, reports the local Vanguard newspaper.

Expressing their fears at a world press conference in Lagos, they stated that implementation of the NDDG which began July 1, 2015, has handed over the pharmaceutical industry to cartels and syndicates and in return, would increase the cost of essential medicines in the country.

They also demanded that the implementation of the policies should be deferred and be refined to reasonably accommodate all stakeholders.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK